Account

Background Heartbeat

SAHPRA Section 21 Step by Step: You Are Not the Applicant

A doctor at a computer in a consulting room, the prescriber who submits a SAHPRA Section 21 application

A SAHPRA Section 21 authorisation is the written permission that lets an unregistered medicine be sold to one named patient, in a specified quantity, over a specified period. Almost everyone who goes looking for one starts in the wrong place, because the application is not yours to make. Regulation 29 puts it in the hands of the health care provider responsible for your care, and an individual named patient request is typically processed within 24 working hours of receipt. The step that decides whether you keep access is not the first application at all. It is a report due every six months.

Last updated:

Key takeaways

  • The applicant is the health care provider responsible for your care, never the patient. There is no patient application form and no patient portal.
  • Section 21 of Act 101 of 1965 lets the Authority authorise a person to sell, during a specified period, to a specified person, a specified quantity of a named unregistered medicine.
  • Screening rejects a request asking for more than six months of supply, and requires the prescriber registration number on the form.
  • A progress report is due every six months, and a further report 30 days after treatment stops. Until that report is in, a new application cannot be submitted on the prescriber profile.
  • An authorisation is not an opinion that the medicine is safe, effective or of acceptable quality, and it does not oblige any licence holder to supply it.

Working out how the SAHPRA Section 21 route is structured before your next appointment? Creating an account is the one part of the process that is entirely in your own hands today.

Register for Store Access

What a SAHPRA Section 21 authorisation actually authorises

Section 21(1) of the Medicines and Related Substances Act 101 of 1965 is one sentence, and every word in it does work. The Authority may in writing authorise any person to sell, during a specified period, to any specified person or institution, a specified quantity of any particular medicine that is not registered.

Read it slowly and you notice who it is addressed to. The permission is granted to the party doing the selling, not to you. You appear in it as the specified person. The quantity is fixed, the period is fixed, and section 21(2) lets the Authority determine in writing the purposes, manner and period of use. Section 21(3) lets it withdraw the whole authority in writing if those determinations are not followed.

So the document is closer to a licence with your name inside it than to a permit you hold, and it sits alongside your prescription rather than replacing it. For the wider legal backdrop, our guide to whether cannabis is legal in South Africa sets out what is decriminalised and what is still a criminal offence.

Who applies, and why it is never you

Regulation 29(1) of the General Regulations says a person desiring to sell an unregistered medicine shall apply to the Authority on an application form. The SAHPRA guideline is more specific for the individual named patient scenario: the application shall be submitted by the health care provider responsible for the care of the patient.

That single rule explains most of the confusion. Patients search for a form and find only industry documents, because the patient-facing step does not exist. What exists instead is a consultation. Your prescriber decides the medicine is clinically appropriate, and only then does paperwork move, submitted through the online portal on the SAHPRA E-services tab.

The prescriber does not act alone either. The application must name the entity licensed under section 22C(1)(b) of the Act to manufacture, import, wholesale or distribute the product, because somebody with a licence has to be the one actually selling it. Understanding which doctors prescribe cannabis medicine in South Africa is therefore the real first step for a patient, not hunting for an application form.

What has to be inside the application

Regulation 29(2) lists the minimum contents. Some of it only a manufacturer can supply. Some of it comes directly out of your own history, which is the part worth preparing for.

What the application must contain Where it comes from
A duly completed application form The prescriber
A product brochure with chemical, pharmaceutical, pre-clinical and clinical data The supplier or manufacturer
A witnessed informed consent document, where applicable You, with your prescriber
Details of registration or pending registration with any other regulator The supplier
Evidence the manufacturer meets Good Manufacturing Practice standards The manufacturer
Reasons why a South African registered medicine cannot be used Your clinical record
The prescribed fee, and any further information the Authority requests The applicant

Line six is the one patients underestimate. Section 21 access is meant to be an exception, for when conventional therapies have been considered and ruled out, have failed, are unsuitable or are unavailable as marketed products. The evidence for that is your own treatment history, so what you can document about earlier medicines, doses and side effects is not small talk. It is a required element of the file.

Before you start

In South Africa, medical cannabis containing THC is prescription only through a registered doctor, usually via a SAHPRA Section 21 authorisation. This page is general information for adults aged 18 and over, not medical advice, and it is not a route to obtaining cannabis outside the law. Speak to a doctor or pharmacist before starting, stopping or changing any treatment, especially about dosing.

The steps in order, and how long each one takes

The guideline splits what happens after submission into screening, evaluation and communication of the outcome. Screening is mechanical. The Section 21 Unit checks that every part of the form is complete, that contact details for the applicant and any co-applicant are present, that the information is legible, that the quantity requested is six months of supply or less, and that the health care provider has given a registration number. Anything critical missing comes back to the applicant in writing.

Evaluation is judgement. It is done case by case, weighing the seriousness of the condition, your clinical status and prognosis, what has already been tried and failed or ruled out, other medicines you are taking, prior experience with the medicine, the quality of the supporting data, the regulatory status of the product elsewhere, and whether a clinical trial is an option for you instead.

The Unit runs 24 hours a day throughout the year, with regular business hours on weekdays from 08:00 to 16:00. After hours contact is reserved for life-threatening situations that need immediate attention, and a telephonic application still has to be followed by the normal submission. An individual named patient application is typically processed within 24 working hours of receipt, and more complex scenarios take longer. The outcome is emailed to the applicant, with co-applicants copied where required.

What SAHPRA weighs against the clock

An hourglass on a desk, the six month reporting cycle behind every SAHPRA Section 21 authorisation

Six months is the number that governs this route, and it appears three separate times. The quantity applied for may not exceed six months of supply. A progress report is due after every six months from the date following commencement of use. And a treatment plan for stock held by a practice should not exceed six months of requirements.

Regulation 29(3) adds two more reporting duties: any adverse event report, and a progress report 30 days after the use of the medicine is completed or terminated. The guideline then states the consequence plainly. A progress report must be submitted before new applications can be submitted on the treating practitioner profile.

A lapse in reporting does not simply annoy the regulator, it blocks the next application at source. If your supply has ever stopped for no reason anyone could explain, an outstanding report is one of the ordinary explanations. Reports go to the Section 21 Unit by email, and serious unexpected adverse reactions have their own deadlines: within 15 days of the prescriber becoming aware, or seven days if the reaction is fatal or life-threatening.

If you have read this far because you are weighing up the SAHPRA Section 21 route rather than an informal supply, registering with Professor Green is where the legal side of that journey begins.

Create Your Professor Green Account

What the authorisation does not do

A health care worker handling packaged medicine, the specified quantity a section 21 authorisation covers

The guideline is unusually direct here, and these four limits are worth knowing before you build expectations on a yes.

First, medicines accessed this way do not undergo the benefit and risk assessment applied to a registration submission or a clinical trial application, so an authorisation does not constitute an opinion that the medicine is safe, effective or of acceptable quality. Second, it does not permit sale outside the conditions stipulated in it. Third, it does not compel a licence holder to sell the medicine at all, which is why an approval can exist while supply still fails commercially.

Because an authorisation is not a verdict on how well a medicine works, the evidence question stays open and is worth answering separately. For the indication people ask about most, our review of what the evidence shows on medical cannabis for chronic pain sets out how large the measured benefit actually is.

Fourth, advertising and marketing of unregistered medicines accessed through Section 21 is strictly prohibited as a general condition of authorisation. That gives you a blunt, useful test in a market full of noise. Anyone advertising a specific unregistered cannabis medicine to you by name is not showing you how compliant they are.

Two smaller rules close off a common assumption. Unused supplies should as a general rule go back to the section 22C(1)(b) licence holder, and moving them to a different patient requires a fresh Section 21 application. Leftover medicine authorised for you is not yours to pass on. Records of what was supplied must be kept, recommended at no less than five years, and the Unit may ask anyone in the chain to reconcile the quantities authorised, procured and used. If the dispensing end of that chain is what you want to understand, our national cannabis dispensary guide covers who may lawfully dispense and who may not.

What happens when an application is refused

A refusal is communicated by email with the reasons for the decision given. The guideline then records something many patients never hear: the applicant may reply to the Section 21 Unit by email to discuss those reasons and, where applicable, the process for submitting a new application with additional information.

A no is therefore a stage, not a wall. It usually means the file did not yet establish an unmet medical need or did not carry credible enough evidence, and both of those are things a prescriber can strengthen. Credible evidence, in the guideline sense, is usually an investigator brochure, prescribing information from a jurisdiction where the medicine is marketed, or peer-reviewed medical literature.

Separately, the Authority may impose additional conditions, request more information, inspect the site where the medicine is manufactured, stored or administered, or withdraw an authorisation where it believes patient safety is compromised or the scientific reasons for use have changed. Access granted is access that stays conditional.

How Professor Green fits into the process

Professor Green is a South African platform that helps people find the legal, prescriber-led route to medical cannabis. Registering creates your account and opens the member area, and that is what registration itself gives you. It is a first step, not an approval and not a guarantee of eligibility, stock or supply.

Professor Green does not apply for a SAHPRA Section 21 authorisation on your behalf, and no platform can. That application belongs to the health care provider responsible for your care, exactly as regulation 29 and the guideline require. A registered prescriber assesses you and decides whether a cannabis medicine is appropriate. SAHPRA decides whether to authorise an unregistered product for you by name. A licensed entity supplies it, and a pharmacy entitled to dispense it hands it over against the prescription. Those are four separate parties with four separate mandates, and Professor Green is not standing in for any of them. For the full route from first appointment onward, read our pillar guide on how to get medical cannabis legally in South Africa.

Sources and references

Patients sometimes assume a Section 21 route replaces a licence they need to buy. It does not, and there is no such licence: see the weed license cost in South Africa for why.

One quiet benefit of the authorised route is documentary. A product that reaches a patient through it carries professional information written to a regulated standard, which is the contrast drawn in our guide to the side effects of weed.

Frequently asked questions

Can a patient apply for a SAHPRA Section 21 authorisation directly?

No. The guideline requires the application to be submitted by the health care provider responsible for the care of the patient, and regulation 29(1) frames the applicant as the person wishing to sell the unregistered medicine. There is no patient application form and no patient submission portal.

How long does a SAHPRA Section 21 application take?

An individual named patient application is typically processed within 24 working hours of receipt. More complex scenarios, such as multiple patient applications held by a health establishment, take longer because there is more information to review. Requests are triaged so that urgent matters take precedence.

How much medicine can one authorisation cover?

Screening checks that the quantity requested is six months of supply or less. A request for more than that will not pass screening in its submitted form, which is why continuing treatment is handled through repeat applications rather than one large one.

Why did my repeat application stall?

One ordinary cause is an outstanding progress report. The guideline states that a progress report must be submitted before new applications can be submitted on the treating practitioner profile, so an overdue six month or end of treatment report blocks the next request until it is filed.

Does an authorisation mean SAHPRA considers the medicine safe?

No. The guideline states that medicines accessed through Section 21 do not undergo the benefit and risk assessment applied to registration submissions, and that authorisation does not constitute an opinion that a medicine is safe, efficacious or of acceptable quality. It is permission to supply in defined circumstances, not an endorsement.

What does the application cost?

A prescribed fee applies per the latest gazetted SAHPRA fee schedule, and it must accompany the application. For multiple patient applications it is multiplied by the number of patients covered, with narrow exceptions such as out of stock registered equivalents. Ask your prescriber what the current figure is before you commit.

What happens if the application is refused?

SAHPRA emails the applicant with the reasons for the decision. The applicant may reply to the Section 21 Unit to discuss those reasons and, where applicable, the process for submitting a new application with additional information. A refusal usually reflects a gap in the evidence rather than a permanent bar.

Can leftover medicine be given to someone else?

No. Unused supplies should as a general rule be returned to the licence holder that supplied them, and transferring them to a new patient requires a fresh Section 21 application. An authorisation names one patient, one quantity and one period.

The short version

A SAHPRA Section 21 authorisation is applied for by your prescriber, decided case by case against the alternatives you have already tried, granted for a named patient and a fixed quantity, and kept alive by a report every six months. Knowing that changes what you do next. You do not chase a form. You find a prescriber who works this route properly, arrive with your treatment history in order, and understand that the reporting cycle is part of the treatment rather than admin that happens elsewhere.

Ready to start the legal route?

If you have been researching how a SAHPRA Section 21 authorisation works and want to explore Professor Green, the next step is to create your account. Registration opens the member area and begins the access journey. It is not a prescription, an approval or a guarantee of supply.

Register for Professor Green Store Access

Share the Post:

Related Posts

Professorgreen.co.za is ran by Green Tec LLC is an authorised marketing affiliate for the Dr Green network who holds the Medical Cannabis licences in South Africa. We do not sell, handle, or ship cannabis. All cannabis products are sold and fulfilled by licensed operator DR Green.

Our Social